{
  "id": "map_1680",
  "title": "HYVET (2008)\\NHypertension in the Very Elderly Trial\\N\\N‚≠ê Estudio pivote HTA en ‚â•80 a√±os",
  "specialty": "Estudios Pivotales",
  "tag": "‚≠ê Estudio Pivotal",
  "node_count": 34,
  "root": {
    "text": "HYVET (2008)\\NHypertension in the Very Elderly Trial\\N\\N‚≠ê Estudio pivote HTA en ‚â•80 a√±os",
    "children": [
      {
        "text": "üìã IDENTIFICACI√ìN",
        "children": [
          {
            "text": "Acr√≥nimo\\NHYpertension in the Very Elderly Trial",
            "children": []
          },
          {
            "text": "Publicaci√≥n\\NNEJM 2008;358:1887-98\\NDOI: 10.1056/NEJMoa0801369",
            "children": []
          },
          {
            "text": "Financiamiento\\NBritish Heart Foundation",
            "children": []
          }
        ]
      },
      {
        "text": "üî¨ DISE√ëO",
        "children": [
          {
            "text": "Tipo\\NRCT doble ciego\\NPlacebo-controlado",
            "children": []
          },
          {
            "text": "Pa√≠ses\\N195 centros, 13 pa√≠ses\\N(Europa, China, Australasia)",
            "children": []
          },
          {
            "text": "Per√≠odo\\N2001-2007\\NSeguimiento: 1.8 a√±os\\NTerminado precozmente",
            "children": []
          }
        ]
      },
      {
        "text": "üë• POBLACI√ìN",
        "children": [
          {
            "text": "n = 3845 aleatorizados\\N1933 indapamida\\N1912 placebo",
            "children": []
          },
          {
            "text": "Criterios inclusi√≥n\\N‚Ä¢ Edad ‚â•80 a√±os\\N‚Ä¢ PAS 160-199 mmHg\\N‚Ä¢ PAD menor a 110 mmHg",
            "children": []
          },
          {
            "text": "Exclusi√≥n\\N‚Ä¢ HTA secundaria\\N‚Ä¢ IC que requiere antiHTA\\N‚Ä¢ Demencia\\N‚Ä¢ Dependencia",
            "children": []
          },
          {
            "text": "Edad media: 83.6 a√±os\\N60.5% mujeres\\NPA: 173/90 mmHg",
            "children": []
          }
        ]
      },
      {
        "text": "üíä INTERVENCI√ìN",
        "children": [
          {
            "text": "Grupo activo\\NIndapamida SR 1.5 mg/d√≠a\\N¬± Perindopril 2-4 mg",
            "children": []
          },
          {
            "text": "Meta: PA menor a 150/80 mmHg",
            "children": []
          }
        ]
      },
      {
        "text": "üìä OUTCOMES",
        "children": [
          {
            "text": "Outcome primario\\NACV fatal o no fatal\\NHR 0.70 (0.49-1.01) p=0.06\\N‚Üì30% (no significativo)",
            "children": []
          },
          {
            "text": "Outcomes secundarios ‚≠ê\\N‚Ä¢ Mortalidad total: ‚Üì21% p=0.02\\N‚Ä¢ IC: ‚Üì64% p menor a 0.001\\N‚Ä¢ ACV fatal: ‚Üì39%",
            "children": []
          },
          {
            "text": "NNT\\N‚Ä¢ ACV: 40 a 2 a√±os\\N‚Ä¢ Mortalidad: 40 a 2 a√±os",
            "children": []
          }
        ]
      },
      {
        "text": "‚ö†Ô∏è SESGOS",
        "children": [
          {
            "text": "Limitaciones\\N‚Ä¢ Terminado precozmente\\N‚Ä¢ Run-in period\\N‚Ä¢ Excluye dementes/fr√°giles\\N‚Ä¢ Seguimiento corto",
            "children": []
          },
          {
            "text": "Sesgo selecci√≥n\\NNo aplica a poblaci√≥n\\Ngeri√°trica real (fr√°giles)",
            "children": []
          }
        ]
      },
      {
        "text": "üè• GERIATR√çA",
        "children": [
          {
            "text": "Fortalezas\\N‚Ä¢ √önico RCT en ‚â•80 a√±os\\N‚Ä¢ Meta conservadora 150/80",
            "children": []
          },
          {
            "text": "Precauciones\\N‚Ä¢ No aplica a fr√°giles\\N‚Ä¢ Vigilar hipotensi√≥n ortost√°tica\\N‚Ä¢ Evaluar expectativa vida",
            "children": []
          }
        ]
      },
      {
        "text": "üíé PERLAS CL√çNICAS",
        "children": [
          {
            "text": "1. Primer RCT que demuestra\\Nbeneficio tratar HTA en ‚â•80",
            "children": []
          },
          {
            "text": "2. Meta 150/80 es razonable\\Nen muy ancianos",
            "children": []
          },
          {
            "text": "3. ‚ÜìIC 64% inesperado",
            "children": []
          },
          {
            "text": "4. NO aplica a fr√°giles/dementes",
            "children": []
          }
        ]
      },
      {
        "text": "üìö Referencias",
        "children": [
          {
            "text": "1. Beckett NS, et al. NEJM 2008\\N2. Peters R, Lancet Neurol 2008",
            "children": []
          }
        ]
      }
    ]
  },
  "related_maps": [
    {
      "id": "map_1633",
      "title": "ACV: ESCALAS DE UTILIDAD CL√çNICA"
    },
    {
      "id": "map_1640",
      "title": "Aciclovir (ACV) versus Valaciclovir (VACV)"
    },
    {
      "id": "map_1055",
      "title": "Biomarcadores en demencia"
    },
    {
      "id": "map_1090",
      "title": "CARGA DEL CUIDADOR Y SERVICIOS DE APOYO EN DEMENCIA"
    },
    {
      "id": "map_1041",
      "title": "Continuum. Demencia Frontotemporal (DFT)"
    }
  ],
  "source_file": "HYVET-2026.smmx",
  "created": "2026-02-07T15:42:53.263054"
}